leisure time -WSS

leisure time

author：explore 2025-09-29 22:51:51 - browse：74

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： NIH launches clinical trials and new research office for long Covid

WSS

Cheap, fast test for Zika and dengue could cost just $1

Medical device trials still don't enroll enough women, study finds

Cigna wins case to block Amy Bricker's move to CVS

My daughter's legacy lives on through her writing, phage therapy

Vertex non

Lawsuit alleges UnitedHealth Group unit illegally denied claims

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

How one medical school became remarkably diverse

Wildfire pollution widens asthma inequities on Long Island

In Memoriam: Notable people who died in 2023

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Heart attack and stroke risk calculators need revising

What to expect as Trump is arraigned on his Jan 6. indictment

In age of alternative facts, a scholarly course on calling out crap

Wildfire pollution widens asthma inequities on Long Island

Medicare details structure of new drug price negotiation program

Physician groups backed by private equity giant lobby on mergers

hotspot

5 important ways Henrietta Lacks changed medical science

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Pence says 'crackpot lawyers' told Trump what he wanted to hear

‘Oppenheimer’ and the risks of AI in health care

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Study: Why relieving medical debt did not improve financial outcomes

Wikipedia

hotspot

hotspot

explore